Chemical Works of Gedeon Richter Plc Logo

Chemical Works of Gedeon Richter Plc

Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.

RICHT | BUD

Overview

Corporate Details

ISIN(s):
HU0000067624 (+3 more)
LEI:
549300J6ZJW5IH4WEE46
Country:
Hungary
Address:
GYOMROI UT 19-21, 1103 BUDAPEST
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemical Works of Gedeon Richter Plc. is a multinational, vertically integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of medicinal products. The company's core therapeutic areas include women's health, central nervous system disorders, and cardiovascular diseases, with additional activity in oncology. Its portfolio consists of original research drugs, active pharmaceutical ingredients (APIs), and generic medicines. Founded in 1901, Gedeon Richter focuses on delivering high-value therapies to improve the quality of life for patients globally.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 12:59
Related Party Transaction
Subsidiaries transactions Q1-Q3 2025
English 179.1 KB
2025-11-06 12:59
Related Party Transaction
Subsidiaries transactions Q1-Q3 2025
Hungarian 238.5 KB
2025-11-06 06:03
Investor Presentation
edeon Richter Plc. - Company presentation Q3 2025
Hungarian 1.4 MB
2025-11-06 06:03
Investor Presentation
edeon Richter Plc. - Company presentation Q3 2025
English 1.4 MB
2025-10-31 14:11
Regulatory News Service
Voting rights, registered capital
Hungarian 244.7 KB
2025-10-31 14:11
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
English 207.0 KB
2025-10-09 10:32
Regulatory News Service
Half-year report for the period ended 30 June 2025 published on August 6, 2025…
Hungarian 1.4 MB
2025-10-09 10:32
Interim Report
Half-year report for the period ended 30 June 2025 published on August 6, 2025…
English 1.4 MB
2025-09-30 14:34
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
Hungarian 243.0 KB
2025-09-30 14:34
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
English 206.1 KB
2025-09-29 08:00
Regulatory News Service
Richter and Hikma receive FDA approval for denosumab biosimilars EnobyTM and Xt…
Hungarian 420.4 KB
2025-09-29 08:00
Regulatory News Service
Richter and Hikma receive FDA approval for denosumab biosimilars EnobyTM and Xt…
English 357.7 KB
2025-09-01 10:29
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
Hungarian 243.4 KB
2025-09-01 10:29
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
English 207.0 KB
2025-08-27 17:35
Regulatory News Service
The European Commission approves Bio-Thera’s BAT2206 (USYMRO®, a biosimilar ust…
Hungarian 334.5 KB

Automate Your Workflow. Get a real-time feed of all Chemical Works of Gedeon Richter Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemical Works of Gedeon Richter Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chemical Works of Gedeon Richter Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.